Sensus Healthcare, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting a nine-month net loss of $12,868 thousand and a third-quarter net loss of $1,493 thousand.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $12,868 thousand for the nine months ended September 30, 2026, compared to a net loss of $4,552 thousand for the same period in 2025.
  • Nine-month revenue decline: Revenues for the nine months ended September 30, 2026 were $11,679 thousand, down from $22,543 thousand in the comparable prior-year period.
  • Q3 revenues: Third-quarter revenues were $5,995 thousand, compared to $6,884 thousand in Q3 2025.
  • Accumulated deficit: Stockholders' equity shifted from retained earnings of $5,715 thousand at December 31, 2025 to an accumulated deficit of $7,153 thousand at September 30, 2026.
  • Cash position: Cash, restricted cash, and cash equivalents totaled $12,920 thousand at September 30, 2026, down from $22,083 thousand at December 31, 2025.
  • Deferred tax asset eliminated: The deferred tax asset of $4,079 thousand recorded at December 31, 2025 was reduced to zero at September 30, 2026, with a tax provision of $4,079 thousand recorded for the nine-month period.
  • Shares outstanding: As of November 10, 2026, there were 16,462,059 shares of common stock outstanding.

Sensus Healthcare Q3 2026: Revenue Contraction and Widening Losses

According to the filing, Sensus Healthcare (NASDAQ:SRTS) reported total revenues of $5,995 thousand for the three months ended September 30, 2026, compared with $6,884 thousand in the same quarter of 2025. For the nine-month period, revenues fell to $11,679 thousand from $22,543 thousand in the prior-year nine-month period. Gross profit for the nine months ended September 30, 2026 was $5,047 thousand, against $9,970 thousand in the prior-year period, the company disclosed.

The filing reported a loss from operations of $9,157 thousand for the nine months ended September 30, 2026, compared with an operating loss of $7,159 thousand for the same period in 2025. Total operating expenses for the nine months were $14,204 thousand, with general and administrative expenses at $6,079 thousand, selling and marketing at $4,319 thousand, and research and development at $3,806 thousand. For the third quarter alone, the company reported a loss from operations of $1,619 thousand, compared to $2,569 thousand in Q3 2025.

On the balance sheet, total assets declined to $40,551 thousand at September 30, 2026, from $53,039 thousand at December 31, 2025. The company's deferred tax asset, which stood at $4,079 thousand at year-end 2025, was fully recognized as a tax provision during the nine-month period, according to the filing. Total stockholders' equity was $35,440 thousand at September 30, 2026, down from $48,098 thousand at December 31, 2025. The filing noted that preferred stock of 5,000,000 shares is authorized with none issued or outstanding.

What Was Disclosed

Sensus Healthcare filed its unaudited quarterly report covering the three and nine months ended September 30, 2026, disclosing revenue declines, widening net losses, a reduced cash balance, and the elimination of its deferred tax asset relative to year-end 2025 figures.